175 related articles for article (PubMed ID: 22789781)
41. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.
Narayan M; Wilken JA; Harris LN; Baron AT; Kimbler KD; Maihle NJ
Cancer Res; 2009 Mar; 69(6):2191-4. PubMed ID: 19276389
[TBL] [Abstract][Full Text] [Related]
42. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
[TBL] [Abstract][Full Text] [Related]
43. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
[TBL] [Abstract][Full Text] [Related]
44. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
45. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma.
Kawaguchi Y; Kono K; Mimura K; Mitsui F; Sugai H; Akaike H; Fujii H
Br J Cancer; 2007 Aug; 97(4):494-501. PubMed ID: 17622245
[TBL] [Abstract][Full Text] [Related]
46. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
[TBL] [Abstract][Full Text] [Related]
47. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
48. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
Cornelissen B; Kersemans V; McLarty K; Tran L; Reilly RM
Cancer Biother Radiopharm; 2009 Apr; 24(2):163-73. PubMed ID: 19409037
[TBL] [Abstract][Full Text] [Related]
49. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations.
Berger C; Krengel U; Stang E; Moreno E; Madshus IH
J Immunother; 2011 Sep; 34(7):550-5. PubMed ID: 21760527
[TBL] [Abstract][Full Text] [Related]
50. Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody.
Wang C; Wang L; Yu X; Zhang Y; Meng Y; Wang H; Yang Y; Gao J; Wei H; Zhao J; Lu C; Chen H; Sun Y; Li B
Oncotarget; 2017 Jun; 8(26):42742-42751. PubMed ID: 28514745
[TBL] [Abstract][Full Text] [Related]
51. A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects
Mohammadi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Arjmand M; Bahadori T; Judaki MA; Shiravi F; Zare HA; Haghighat FN; Mobini M; Amiri MM; Shokri F
Front Immunol; 2020; 11():600883. PubMed ID: 33679691
[TBL] [Abstract][Full Text] [Related]
52. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
53. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM
Acta Pharmacol Sin; 2022 Mar; 43(3):672-680. PubMed ID: 33990766
[TBL] [Abstract][Full Text] [Related]
54. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
55. Bispecific Antibodies for IFN-β Delivery to ErbB2
Rybchenko VS; Panina AA; Aliev TK; Solopova ON; Balabashin DS; Novoseletsky VN; Dolgikh DA; Sveshnikov PG; Kirpichnikov MP
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944558
[TBL] [Abstract][Full Text] [Related]
56. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
[TBL] [Abstract][Full Text] [Related]
57. A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth.
Zhang Y; Wang L; Chong X; Yu X; Meng Y; Dong J; Wang C; Wang H; Yang Y; Xia T; Zhao J; Li B
Biochem Biophys Res Commun; 2016 Sep; 477(4):755-760. PubMed ID: 27363335
[TBL] [Abstract][Full Text] [Related]
58. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.
Zheng S; Moores S; Jarantow S; Pardinas J; Chiu M; Zhou H; Wang W
MAbs; 2016; 8(3):551-61. PubMed ID: 26761634
[TBL] [Abstract][Full Text] [Related]
59. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
[TBL] [Abstract][Full Text] [Related]
60. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]